Skip to content
Medical Health Aged Care

Tilray Medical Wins Tender to Supply Luxembourg with Medical Cannabis

Tilray Brands, Inc. 3 mins read

NEUMÜNSTER, Germany, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), proudly announces that its German subsidiary, Tilray Deutschland GmbH, has secured a tender to supply Luxembourg with its high-quality cannabis flower. The granting of this tender by the Ministry of Healthand Social Security for the Grand Duchy of Luxembourg highlights the trust placed in Tilray Medical to deliver high-quality medical cannabis on a consistent basis across the global medical cannabis industry. Additionally, it reinforces Tilray’s commitment to deliver on Europe’s growing demand for premium medical cannabis products.

Denise Faltischek, Chief Strategy Officer and Head of International, said, "We are honored to have been selected again to supply medical cannabis to Luxembourg. This is a testament to the unwavering dedication of our team in providing patients around the world with high-quality medical cannabis products."

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Broken Coast, Redecan, Good Supply and Navcora. Tilray Medical grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Portugal and Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments in over 20 countries and across five continents.

Further information can also be found here: Pioneering the Future of Medical Cannabis - Tilray EU

About Tilray Brands

Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.

For further information:
Media: [email protected]
Investor Relations: [email protected]


Primary Logo

More from this category

  • Medical Health Aged Care
  • 17/06/2025
  • 18:41
Ferrer

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

BARCELONA, Spain--BUSINESS WIRE-- Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/Ferrer's pharmaceutical production…

  • Contains:
  • Education Training, Medical Health Aged Care
  • 17/06/2025
  • 11:55
SUADA PR

Applications have just opened for the 2025 First Nations Cancer Scholarship Program

MEDIA RELEASE Applications Open for $5.9 Million First Nations Cancer Scholarship Fund Supporting Indigenous leadership in cancer care and research Tuesday, 17 June 2025 Aurora Education Foundation, in partnership with Cancer Australia, is now accepting applications for the 2025 round of the First Nations Cancer Scholarships, a $5.9 million program supporting Aboriginal and Torres Strait Islander leadership in cancer control. Funded by the Australian Government through Cancer Australia, the Scholarship provides up to $120,000 per year up to three years, as well as academic, wellbeing and community support. It is open to Aboriginal and Torres Strait Islander students, health professionals…

  • Medical Health Aged Care
  • 17/06/2025
  • 06:30
RMIT University

New pathway for mRNA drug delivery shows shape of things to come

Scientists have discovered that the internal shape of tiny drug-delivery particles – called lipid nanoparticles – has a big impact on how well our…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.